



HYLOMORPH Secures 3.2 MCHF Series A-Round Lead by Fongit Seed Invest (FSI)

Zurich, Switzerland – HYLOMORPH, a multi-awarded winning Swiss medtech startup and ETHZ spin-off seed-funded by Wyss Zurich, announced it has completed a 3.2 MCHF Series A financing that will allow the company to finalise product development and conduct clinical studies required for FDA approval and CE certification expected in 2021. The Financing round was led by FSI and included experienced business angels from the Start Angel Network Zurich, ZKB and Investiere.

“We are very happy to have secured the funding in such a short time from a diverse and experienced group of investors” says Dr. Simone Bottan, CEO and founder of HYLOMORPH. “The investment will allow us to conclude the last stage of product development and sponsor a clinical trial to obtain CE and FDA market certifications, that will finally authorize our company to enter the EU and US markets.”

“There were several good reasons to invest in HYLOMORPH” says Gianluigi Berini. “Its strong team, the versatile technology platform, the strong endorsement of leading medical and business KOL and a very attractive market combined with a clear exit-strategy is what convinced us the most to invest and to lead the financing round.” Gianluigi Berini and Peter Gabriel, both successful entrepreneurs, will join the company’s Board of Directors.

About HYLOMORPH:

HYLOMORPH solves the problem of fibrotic encapsulation encountered by all implantable medical devices. HYLOMORPH has developed a unique biomaterial which interacts with the sensing mechanism of cells thus maintaining the healthy interaction between device and tissue. Main markets include breast surgery implants and cardiac arrhythmia devices representing a total market opportunity of CHF 2.5bn worldwide.

For further information please visit www.hylomorph-medical.com

Media Contact:

Peter Jackson pj@hylomorph-medical.com